Lineage Cell Therapeutics advances COR1 corneal cell therapy into in-vivo animal testing

Lineage Cell Therapeutics disclosed a preclinical update on COR1, an allogeneic corneal endothelial cell transplant program for corneal endothelial disease.

Manufacturing work met internal thresholds for potency, identity, and scale, and the program moved into in-vivo animal testing with initial data expected this year.

Management expects a two-tier GMP banking system could support production of millions of final-product doses.